Hosted by the European Association for Cancer Research and Boeringer Ingelheim
The Mitogen Activated Protein Kinase (MAPK) pathway is one of the most commonly mutated signaling pathways in human cancers. While a range of small molecule inhibitors have been developed to inhibit the upstream and downstream effectors of this pathway, resistance remains a significant challenge.
This conference will focus on both the basic and clinical aspects of the regulation of signaling through the MAPK pathway and its role in cancer. A thorough understanding of the mechanisms of intrinsic and adaptive resistance is crucial for the development of more effective agents. Additionally, as the MAPK pathway can also contribute to cross-resistance to immune checkpoint blockers, alternative combination therapies and potential targets will also be discussed at the conference.
By examining the regulation of the MAPK pathway and its impact on cancer, there is real potential to make progress in improving treatment outcomes.
Registration deadline: 2 February 2023